No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ASPN240621C30000
- 1.55
- +0.15+10.71%
15min DelayClose May 31 15:59 ET
1.55High0.85Low
1.25Open1.40Pre Close364 Volume2.07K Open Interest30.00Strike Price37.42KTurnover56.95%IV5.45%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry1.55Time Value100Contract SizeAmericanOptions Type0.5261Delta0.1025Gamma19.30Leverage Ratio-0.0433Theta0.0074Rho10.16Eff Leverage0.0272Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 68315.0 Shares on Buy Side
Aspen Aerogels Insider Sold Shares Worth $12,704,618, According to a Recent SEC Filing
Donald R Young, Director, President and Chief Executive Officer, on May 28, 2024, sold 433,690 shares in Aspen Aerogels (ASPN) for $12,704,618. Following the Form 4 filing with the SEC, Young has cont
Express News | Piper Sandler Maintains Overweight on Aspen Aerogels, Raises Price Target to $36
Analysts Offer Insights on Industrial Goods Companies: Terran Orbital Corp (LLAP), Bluelinx Holdings (BXC) and Aspen Aerogels (ASPN)
NYSE New 52-Week Highs And Lows
New Highs 95 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Abercrombie & Fitch ANF 153.20 321,314 A
Aspen Aerogels(ASPN.US) Director Sells US$122.03K in Common Stock
$Aspen Aerogels(ASPN.US)$ Director Kool Kathleen sold 4,470 shares of common stock on May 22, 2024 at an average price of $27.3 for a total value of $122.03K.Source: Announcement What is statement of
Comments
#ASPN up over $16.50 a share, trying to decide if to pull the trigger and sell or hold for a little longer.
3
$Aspen Aerogels(ASPN.US$ let's gp
2
Aspen Aerogels' high P/S ratio is backed by strong revenue growth, outpacing the Chemicals industry. Investors' confidence in future revenues supports the high P/S ratio and share price. Yet, the company's prospects shouldn't be judged solely on the P/S ratio.
Aspen Aerogel's high P/S ratio is echoed by strong revenue growth, surpassing industry standard. With impressive growth forecasts exceeding industry estimates, the high P/S ratio is justifiable. The stock's rising trend indicates shareholders foresee continued outperformance, with no sharp drop in share price anticipated soon.
Aspen Aerogels has drawn concerns due to its liabilities and absence of EBIT level profitability despite observing 41% revenue growth. Given the debt usage, its current state appears risky, necessitating close monitoring of balance sheet and understanding the high risks tied to the stock.
Read more